Key Points
- VP Padmanabh Bhatt sold 50,000 shares on March 16 at an average of $50.28 per share for a total of $2,514,000, reducing his ownership by 74.58% to 17,044 shares (about $857,000).
- Shares opened at $49.29 and were trading down ~3%; the company has a $2.84 billion market cap, a negative P/E of -72.48, and a 12‑month range of $29.16 to $59.68.
- Analyst coverage is mixed with a consensus rating of "Hold" and an average price target of $62.17 (four Buys, one Hold, two Sells).
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) VP Padmanabh Bhatt sold 7,250 shares of the company's stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $49.60, for a total transaction of $359,600.00. Following the sale, the vice president directly owned 17,044 shares of the company's stock, valued at approximately $845,382.40. This represents a 29.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Supernus Pharmaceuticals Price Performance
Shares of Supernus Pharmaceuticals stock opened at $49.29 on Thursday. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $59.68. The company's fifty day simple moving average is $51.22 and its 200-day simple moving average is $49.17. The stock has a market capitalization of $2.84 billion, a PE ratio of -72.48, a P/E/G ratio of 1.58 and a beta of 0.70.
Hedge Funds Weigh In On Supernus Pharmaceuticals
Several large investors have recently made changes to their positions in SUPN. Rockefeller Capital Management L.P. boosted its stake in Supernus Pharmaceuticals by 354.8% during the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock valued at $42,000 after buying an additional 660 shares during the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $237,000. Sit Investment Associates Inc. boosted its position in shares of Supernus Pharmaceuticals by 0.4% during the 4th quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company's stock valued at $3,240,000 after acquiring an additional 250 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Supernus Pharmaceuticals by 9.4% in the fourth quarter. Invesco Ltd. now owns 395,761 shares of the specialty pharmaceutical company's stock valued at $19,669,000 after purchasing an additional 33,895 shares in the last quarter. Finally, Mackenzie Financial Corp purchased a new position in shares of Supernus Pharmaceuticals in the fourth quarter valued at $223,000.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on SUPN shares. Zacks Research downgraded Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Thursday, January 29th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Sunday, March 8th. Stifel Nicolaus increased their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a "hold" rating in a report on Friday, December 19th. Finally, Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $62.17.
Check Out Our Latest Analysis on SUPN
Supernus Pharmaceuticals Company Profile
(
Get Free Report)
Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.
The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
